|Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA||Founder & Exec. Chairman||13.76M||N/A||1972|
|Dr. Kunwar Shailubhai||CEO, Chief Scientific Officer & Exec. Director||810k||N/A||1958|
|Dr. Andrea Brancale||Scientific Founder||N/A||N/A||N/A|
|Mr. Richard Clarkson Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Mr. Andrew Westwell Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Ms. Keeren Shah||Fin. Director||N/A||N/A||1977|
|Dr. Thomas H. Adams||Head of Drug Devel. & Exec. Director||N/A||N/A||1943|
|Dr. Neil Graham M.P.H., MBBS, M.D., MPH||Chief Medical Officer||N/A||N/A||1959|
|Dr. Napoleone Ferrara||Chairman of Scientific Advisory Board||N/A||N/A||1958|
|Prof. Roberto Pellicciari||Consultant||N/A||N/A||N/A|
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Tiziana Life Sciences PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.